SCD and ovarian carcinoma: The combined treatment of olaparib and arsenic trioxide (ATO) activates the AMPKα pathway and inhibits SCD1 expression, resulting in a significant increase in lipid peroxide in ovarian cancer cells, which induces the occurrence of ferroptosis (67).However, BRCA (wild type) ovarian cancer can produce olaparib resistance by repairing PARPi-induced DNA damage.